A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Latest Information Update: 15 Jul 2024
At a glance
- Drugs JNJ 73763989 (Primary) ; Entecavir; Peginterferon alfa-2a; Tenofovir alafenamide; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PENGUIN
- Sponsors Janssen Research & Development
- 15 May 2023 Status changed from active, no longer recruiting to completed.
- 16 Mar 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 08 Nov 2022 Primary endpoint (Percentage of Participants with a Reduction of at Least 2 log10 IU/mL in Hepatitis B Surface Antigen (HBsAg) Levels) has been met, as per results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.